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Abstract
Background: Patients with ankylosing spondylitis (AS) are at increased risk of developing inflammatory bowel
disease (IBD). We aimed to determine the variation in fecal calprotectin in AS over 5 years in relation to disease
activity and medication and also to study the incidence of and predictors for development of IBD.
Methods: Fecal calprotectin was assessed at baseline (n = 204) and at 5-year follow-up (n = 164). The patients
answered questionnaires and underwent clinical evaluations. At baseline and at 5-year follow-up, ileocolonoscopy
was performed in patients with fecal calprotectin ≥500 mg/kg and ≥200 mg/kg, respectively. The medical records
were checked for diagnoses of IBD during the follow-up period.
Results: Fecal calprotectin >50 mg/kg was found in two-thirds of the patients at both study visits. In 80% of the
patients, fecal calprotectin changed by <200 mg/kg between the two measuring points. Baseline fecal calprotectin
was positively correlated with Ankylosing Spondylitis Disease Activity Score based on C-reactive protein, Bath
Ankylosing Spondylitis Disease Activity Index, Bath Ankylosing Spondylitis Functional Index, C-reactive protein,
erythrocyte sedimentation rate, and fecal calprotectin at 5-year follow-up. The use of nonsteroidal anti-inflammatory
drugs (NSAIDs) was associated with higher fecal calprotectin, and 3-week cessation of NSAIDs resulted in a drop of
a median 116 mg/kg in fecal calprotectin. The use of tumor necrosis factor (TNF) blockers was associated with
lower fecal calprotectin at both visits, but the users of TNF receptor fusion proteins had significantly higher fecal
calprotectin than users of anti-TNF antibodies at 5-year follow-up. The 5-year incidence of Crohn’s disease (CD) was
1.5% and was predicted by high fecal calprotectin.
Conclusions: Fecal calprotectin was elevated in a majority of the patients and was associated with disease activity and
medication at both visits. CD developed in 1.5% of the patients with AS, and a high fecal calprotectin was the main
predictor thereof. The results support a link between inflammation in the gut and the musculoskeletal system in AS.
We propose that fecal calprotectin may be a potential biomarker to identify patients with AS at risk of developing IBD.
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Background
Ankylosing spondylitis (AS), Crohn’s disease (CD), and
ulcerative colitis (UC) are inflammatory diseases that have
many common features. Several risk genes are shared
between the spondylarthritides and inflammatory bowel
disease (IBD), and the diseases can show coinheritance
[1–4]. Patients with IBD can develop peripheral arthritis
(10–20%), sacroiliitis (10–20%), and anterior uveitis (0.5–
3%) [5–9]. Studies have revealed the presence of endo-
scopic and histologic gut inflammation in 40–60% of pa-
tients with AS and in 46% of patients with early
spondylarthritis (SpA) [10–13]. The subclinical gut inflam-
mation in AS is often localized to the colon or the distal
ileum. Histologically, the inflammation has been divided
into an acute form and a chronic form, the latter resem-
bling CD and conferring an increased risk for subsequent
development of IBD [14–16]. Approximately 5–10% of pa-
tients with SpA eventually develop IBD, with CD being
more common than UC [17, 18]. There is a lack of know-
ledge about what predicts the development of IBD in AS,
however, and clinical studies on the subject are rare [19].
Fecal calprotectin is an unspecific marker for gut inflam-
mation. Calprotectin belongs to the family of calcium-
binding calgranulins (or S100 proteins) and consists of
heterodimers of the two proteins S100A8 and S100A9.
Calprotectin is an abundant protein in the neutrophils, con-
stituting up to 40–60% of the cytosolic protein content, and
it is also found in gut epithelial cells, monocytes, and mac-
rophages. The level of calprotectin in feces is proportional
to the level of neutrophil inflammation in the gut [20].
Fecal calprotectin is clinically used to discriminate IBD
from irritable bowel syndrome and correlates well with
clinical, endoscopic, and histologic measures of disease ac-
tivity in IBD [21, 22]. Fecal calprotectin is also increased in
enteropathy caused by nonsteroidal anti-inflammatory
drugs (NSAIDs) [23].
We have previously investigated the levels of fecal cal-
protectin in a cohort of 204 patients with AS. We found
that 68% of the patients had elevated levels (>50 mg/kg)
and that fecal calprotectin was associated with higher
disease activity but not with gastrointestinal symptoms
[24]. The same patients were then invited to be reexa-
mined at a 5-year follow-up examination.
The aims of this 5-year prospective study on AS were
(1) to investigate the intraindividual variations in fecal
calprotectin over time in relation to disease activity,
disease manifestations, and medication; (2) to study the 5-
year incidence of IBD; and (3) to identify predictors for
the development of IBD.
Methods
Patients
All patients fulfilling the modified New York criteria for
AS who were registered at the rheumatology clinics at
Sahlgrenska University Hospital and the hospitals of Borås
and Alingsås were invited to participate in the study in
2009, hereafter called baseline [24, 25]. Exclusion criteria
were diagnosed IBD, psoriasis, dementia, pregnancy, and
difficulties in understanding the Swedish language.
Altogether, 204 patients were included at baseline and 164
(80%) patients were reexamined at the 5-year follow-up in
2014. All patients gave their written informed consent.
The study was approved by the regional ethics committee
in Gothenburg and was carried out in accordance with the
Helsinki declaration. A flowchart of the enrollment of the
patients and the study procedures is shown in Fig. 1. The
patients underwent the same assessments at both visits,
including physical examinations and responding to ques-
tionnaires. Blood and stool samples were collected. The
medical records of all the included patients at baseline
were checked for ileocolonoscopies, episodes of gut in-
flammation, or diagnoses of IBD.
Questionnaires
The Ankylosing Spondylitis Disease Activity Score based
on C-reactive protein (ASDASCRP), Bath Ankylosing
Spondylitis Disease Activity Index (BASDAI), Bath
Ankylosing Spondylitis Patient Global Score, and Bath
Ankylosing Spondylitis Functional Index (BASFI) were used
to assess disease activity and physical function. Back mobil-
ity was measured for the calculation of Bath Ankylosing
Spondylitis Metrology Index (BASMI) [26].
Stool samples
Stool samples were collected by the patients and sent to
the laboratory, where the samples were immediately fro-
zen. After thawing of the samples, fecal calprotectin was
analyzed using an enzyme-linked immunosorbent assay
(ELISA) kit (Bühlmann Laboratories AG, Schönenbuch,
Switzerland). The same ELISA kit and procedures were
used at baseline and at 5-year follow-up. In the general
population, fecal calprotectin is <50 mg/kg, according to
the manufacturer of the kit.
Blood samples
Blood samples were analyzed for hemoglobin, erythrocyte
sedimentation rate (ESR), and C-reactive protein (CRP)
using standard laboratory techniques. Serum calprotectin
was analyzed at baseline by ELISA (PhiCal; Immundiag-
nostik AG, Bensheim, Germany) following the manufac-
turer’s instructions. According to the manufacturer, the
normal range for serum calprotectin is 500–3000 ng/ml.
Ileocolonoscopy
At baseline, all patients with fecal calprotectin ≥500 mg/kg
were asked to send in a new stool sample. NSAID use was
not stopped. If their fecal calprotectin remained ≥500 mg/
kg, the patients were advised to undergo a clinical routine
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ileocolonoscopy (Fig. 1). At 5-year follow-up, all patients
with fecal calprotectin ≥200 mg/kg were asked to send in
another stool sample after pausing NSAID medication for
3 weeks. If their fecal calprotectin remained >200 mg/kg
when retested, the patients were referred for ileocolono-
scopy. Before the ileocolonoscopy, NSAIDs were again
paused for 3 weeks. At 5-year follow-up, all ileocolonosco-
pies were performed by one endoscopist (HS) and followed
the same procedure.
Data analyses
Data from all patients who participated at baseline (n =
204) were analyzed with the aim of determining the 5-year
incidence of IBD and the predictors thereof. For all other
data analyses, only the patients who participated both at
baseline and at 5-year follow-up (n = 164) were included.
Statistical analyses
Statistical analyses were performed using IBM SPSS Statis-
tics 23 software (IBM, Armonk, NY, USA). Descriptive sta-
tistics are presented as median and IQR. In comparisons
between groups, the Mann-Whitney U test was used for
continuous variables, and the chi-square test or Fisher’s
exact test was used for categorical variables. The Wilcoxon
signed-rank test was used for repeated measurements.
Correlations were calculated using Spearman’s correlation
(rs). Owing to its skewed distribution, fecal calprotectin was
log-transformed and used as an outcome in linear regres-
sion with a stepwise model. All tests were two-tailed, and
p ≤ 0.05 was considered statistically significant.
Results
Characteristics of the study population
In total, 164 patients, comprising 45% women and 55%
men, completed the study and were examined at the two
study visits (baseline and 5-year follow-up). The charac-
teristics of the study population are provided in Table 1.
Intraindividual variation in fecal calprotectin between
baseline and 5-year follow-up
Fecal calprotectin was elevated (>50 mg/kg) in 70.7%
(116 of 164) of the patients at baseline and in 63.4%
(104 of 164) of the patients at 5-year follow-up. The
levels of fecal calprotectin did not differ between base-
line and follow-up (p = 0.660) (Table 1).
The change in fecal calprotectin between baseline and the
5-year follow-up was ≤50 mg/ml in 48% of the patients, 51–
100 mg/kg in 16%, and 101–200 mg/kg in 16%. The median
change between baseline and 5-year follow-up for calprotec-
tin was 1.5 (IQR −52.7 to 52.7) mg/kg. The intraindividual
Fig. 1 Flowchart of the study procedures. Ileocolonoscopies were performed at different thresholds of fecal calprotectin at baseline and 5-year
follow-up. F-cal Fecal calprotectin, NSAID Nonsteroidal anti-inflammatory drug
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Table 1 Characteristics of the 164 patients with ankylosing spondylitis at baseline and 5-year follow-up
Baseline 5-Year follow-up p Value
Sex, female/male 74 (45)/90 (55)
Age, years 49.5 (41–62) 54.5 (46–67) <0.001
Years since onset of AS symptoms 22 (13–34) 27 (18–39) <0.001
Years since AS diagnosis 12 (5–23) 17 (10–28) <0.001
HLA-B27-positive 141 (86)
Fecal calprotectin, mg/kg 86 (45–222) 82 (35–190) 0.660
Fecal calprotectin level
≤ 50 mg/kg 48 (29.3) 60 (36.6) 0.660
51–199 mg/kg 69 (42.1) 64 (39.0)
200–499 mg/kg 32 (19.5) 29 (17.7)
500–999 mg/kg 13 (7.9) 8 (4.9)
>1000 mg/kg 2 (1.2) 3 (1.8)
Serum calprotectin, ng/ml 645 (282–705) No data N/A
CRP, mg/L 2 (1–6) 3 (1–6) 0.434
ESR, mm/h 11 (7–18) 8 (4–14) <0.001
ASDASCRP score 2.2 (1.6–3.0) 2.1 (1.3–2.7) <0.001
BASDAI score 3.1 (1.6–5.2) 3.2 (1.8–5.2) 0.713
BAS-G score 2.7 (1.2–5.7) 2.8 (1.4–5.9) 0.187
BASFI score 2.3 (1.0–3.8) 2.3 (1.0-4.1) 0.443
BASMI score 2.8 (2.0–4.0) 3.4 (2.4–4.6) <0.001
Current smoker 15 (9.1) 11(6.7) 0.388
NSAIDs 128 (78) 125 (76) 0.868
Daily use 73 (45) 66 (40)
As needed 55 (34) 59 (36)
TNF blockers 33 (20) 39 (24) 0.238
Infliximab 24 (15) 21 (13) 0.664
Adalimumab 4 (2) 8 (5) 0.289
Golimumab 0 (0) 4 (2) N/A
Etanercept 5 (3) 6 (4) 1.000
DMARDs
Methotrexate 35 (21) 29 (18) 0.189
Sulfasalazine 16 (10) 8 (5) 0.004
Regular occurrence of gastrointestinal symptoms
Loose stools 70 (43) 66 (40) 0.401
Mucus in diarrhea 25 (15) 34 (21) 0.405
Blood in stools 22 (13) 21 (13) 1.000
Blood in diarrhea 8 (5) 9 (5) 1.000
Abdominal pain 24 (15) 33 (20) 0.210
Obstipation 54 (33) 41 (25) 0.008
Reflux symptoms 65 (40) 62 (38) 0.391
Epigastric pain 47 (29) 46 (28) 1.000
Abbreviations: AS Ankylosing spondylitis, CRP C-reactive protein, DMARD Disease-modifying antirheumatic drug, ESR Erythrocyte sedimentation rate, ASDASCRP
Ankylosing Spondylitis Disease Activity Score based on C-reactive protein, BASDAI Bath Ankylosing Spondylitis Disease Activity Index, BAS-G Bath Ankylosing
Spondylitis Patient Global Score, BASFI Bath Ankylosing Spondylitis Functional Index, BASMI Bath Ankylosing Spondylitis Metrology Index, NSAID nonsteroidal anti--
inflammatory drug, TNF tumor necrosis factor
Data are presented as median and [interquartile range] or number (%)
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correlation coefficient for fecal calprotectin at baseline and
follow-up was rS = 0.512 (p < 0.001) (Fig. 2a).
Fecal calprotectin correlates with disease activity and
physical function
At both visits, fecal calprotectin was positively and sig-
nificantly correlated with parameters reflecting higher
disease activity and poorer function at the same visit,
such as CRP, ESR, ASDASCRP, BASDAI, BASFI, and
BASMI. In addition, fecal calprotectin at baseline was
positively associated with higher levels of CRP, ESR,
ASDASCRP, and BASFI at 5-year follow-up (Table 2).
The patients who were smoking at baseline (9%) had,
in comparison with nonsmokers, significantly higher
fecal calprotectin at 5-year follow-up (median [IQR] 107
[43–402] vs. 85 [45–221] mg/kg, p = 0.026). Baseline
serum calprotectin was also positively correlated with
fecal calprotectin, both at baseline (rS = 0.252, p = 0.001)
and at 5-year follow-up (rS = 0.170, p = 0.030).
Fecal calprotectin and medication
The medications used at baseline and 5-year follow-up are
listed in Table 1. Fecal calprotectin was significantly higher
in NSAID users than in nonusers at both study visits (base-
line median [IQR] 105 [45–262] vs. 68 [44–93] mg/kg, p=
0.032; 5-year follow-up 93 [44–215] vs. 40 [23–120] mg/kg,
p= 0.011) (Fig. 3a). The users of anti-tumor necrosis factor
(anti-TNF) antibodies (infliximab, adalimumab, golimumab)
had significantly lower fecal calprotectin than patients
without TNF blocker therapy at both visits (baseline 43
[17–84] vs. 99 [54–256] mg/kg, p = 0.004; 5-year follow-up
48 [26–135] vs. 89 [40–210] mg/kg, p= 0.022), whereas no
such difference was found between users of TNF receptor
fusion proteins (etanercept) and nonusers of TNF blockers.
At 5-year follow-up, the patients treated with TNF receptor
fusion proteins had significantly higher fecal calprotectin
than the patients treated with anti-TNF antibodies (200
[93–555] vs. 48 [26–135] mg/kg; p= 0.016) (Fig. 3b). Come-
dication with methotrexate and a TNF blocker was com-
mon. Methotrexate was mostly taken in low doses (5–
15 mg weekly). At 5-year follow-up, the use of methotrexate
among patients on anti-TNF antibodies was not significantly
different from the use in patients taking etanercept (18 of 33
[54.5%] vs. 2 of 6 [33%]; p= 0.407 by Fisher’s exact test).
Although the patients treated with TNF blockers had a
significantly lower frequency of NSAID intake than the
patients without TNF blockers, the significant differences
in fecal calprotectin between users and nonusers of
disease-modifying antirheumatic drugs and/or TNF
blockers remained after adjustment for NSAID use.
Linear regression analysis was performed with log-
transformed fecal calprotectin at 5-year follow-up as an
outcome measure, and the following baseline values were
used as covariates: sex, age, serum calprotectin, fecal cal-
protectin, CRP, ASDASCRP, BASFI, smoking, and use of
NSAIDs and anti-TNF antibodies/TNF receptor fusion
proteins. Only fecal calprotectin at baseline (β = 0.001, SE
= 0.000, 95% CI 0.0008–0.0015, p < 0.001) and smoking at
Fig. 2 a Scatterplot of fecal calprotectin at baseline and 5-year follow-up in 164 patients with ankylosing spondylitis (AS). b Fecal calprotectin be-
fore and after a 3-week pause of nonsteroidal anti-inflammatory drug (NSAID) use at 5-year follow-up in 33 patients with AS
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baseline (B = 0.241, SE = 0.121, 95% CI 0.002–0.479, p =
0.048) remained independently associated with higher
fecal calprotectin at 5-year follow-up (R2 = 0.247).
Gastrointestinal symptoms
A high frequency of gastrointestinal symptoms (diarrhea,
presence of blood or mucus in stools, obstipation, abdom-
inal pain, tenesmus, reflux symptoms, and epigastric pain)
was reported by the participants both at baseline and at 5-
year follow-up (Table 1). There were no significant associ-
ations between the levels of fecal calprotectin and gastro-
intestinal symptoms at any of the time points, however.
Fecal calprotectin before and after of 3-week NSAID
pause
At 5-year follow-up, the patients who had fecal calpro-
tectin ≥200 mg/kg (n = 40 [24%]) were asked to send in
a new stool sample after pausing NSAID use for 3 weeks,
which a total of 33 patients did. After the 3-week NSAID
pause, fecal calprotectin dropped by 116 (−20 to 289)
mg/kg from a range of 410 (295–510) mg/kg to 290
(120–480) mg/kg (p = 0.005) (Fig. 2b).
Development of gut inflammation during 5 years of
follow-up
Ileocolonoscopies were performed in 8 patients at base-
line and in 16 patients at 5-year follow-up (Fig. 1). The
findings from the ileocolonoscopies are summarized in
Table 3. Altogether, 10 (41.7%) of the 24 patients who
underwent ileocolonoscopy had inflammatory changes
in the gut biopsies. In addition, five patients (20.8%) had
only macroscopic changes.
At 5-year follow-up, 3 patients (1.5%) were diagnosed
with CD (corresponding to an annual incidence of 294
new cases per 100,000 person-years), and 1 patient (0.5%)
was diagnosed with lymphocytic colitis. No cases of UC
Table 2 Spearman’s correlations between fecal calprotectin and parameters reflecting disease activity and physical function at
baseline and 5-year follow-up













FC Baseline 0.280 0.209 0.222 0.169 0.260 0.240 0.190 N.S. 0.166 0.166 N.S. N.S.
p-value < 0.001 p = 0.007 p = 0.004 p = 0.031 p = 0.001 p = 0.002 p = 0.016 p = 0.034 p = 0.034
FC 5-year N.S. 0.219 N.S. 0.172 N.S. 0.207 N.S. N.S. N.S. 0.154 N.S. 0.207
p-value p = 0.005 p = 0.027 p = 0.008 p = 0.048 p = 0.008
Abbreviations: CRP C-reactive protein, ESR Erythrocyte sedimentation rate, ASDASCRP Ankylosing Spondylitis Disease Activity Score based on C-reactive protein,
BASDAI Bath Ankylosing Spondylitis Disease Activity Index, BASFI Bath Ankylosing Spondylitis Functional Index, BASMI Bath Ankylosing Spondylitis Metrology Index,
FC fecal calprotectin
Fig. 3 a Box plot showing the association between fecal calprotectin and frequency of NSAID intake at 5-year follow-up. b Box plot showing the
distribution of fecal calprotectin among patients on anti-TNF antibodies (infliximab, adalimumab, golimumab) vs. no TNF blocker therapy vs. TNF
receptor fusion proteins (etanercept) at 5-year follow-up. Values are median (horizontal lines), IQR (boxes), and total range (whiskers). NSAID
Nonsteroidal anti-inflammatory drug, TNF Tumor necrosis factor
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were found. Additionally, five patients (2.5%) demon-
strated characteristics of subclinical CD with aphthous ul-
cerations and/or chronic inflammation in the distal ileum,
and another six patients (2.9%) had ulcerations and/or
chronic inflammation in the colon. In total, 15 patients
(7.4%) demonstrated characteristics of inflammation in
the large or small intestine during the 5-year follow-up
period.
Predictors for development of CD
At baseline, the patients who developed CD had, in
comparison with the other patients, higher fecal calpro-
tectin (570 [271–570] mg/kg vs. 85 [43–230]; p = 0.014)
and more often reported having diarrhea containing
mucus (3 of 3 vs. 30 of 201; p = 0.004). No significant as-
sociations were found between the development of CD
and the other baseline parameters. A receiver operating
characteristic (ROC) curve was created with baseline
fecal calprotectin as the test variable and development of
CD as the categorical state variable. The area under the
curve was 0.913 (95% CI 0.805–1.000; p = 0.014). Using
a threshold for baseline fecal calprotectin of 266 mg/kg,
based on this ROC curve, the sensitivity for development
of CD was 100% and the specificity was 78.7%.
Discussion
In this longitudinal 5-year study of a well-characterized
cohort of patients with AS, we followed the intraindivi-
dual variation in fecal calprotectin in relation to disease
activity and medication, and we determined the
incidence and predictors for IBD. Fecal calprotectin was
elevated (>50 mg/kg) in approximately two-thirds of the
patients at both the baseline and 5-year follow-up visits.
The intraindividual variation was moderate; in 80% of
the patients, fecal calprotectin changed <200 mg/kg be-
tween the two measurement time points. Smoking and
elevated fecal calprotectin at baseline were the strongest
predictors for high fecal calprotectin at 5-year follow-up.
Of the 204 patients included at baseline, 1.5% were diag-
nosed with CD and 0.5% with lymphocytic colitis at 5-
year follow-up. High fecal calprotectin and presence of
mucus in diarrhea at baseline were the main predictors
of development of CD in this cohort.
Our results indicate that gut inflammation in AS is asso-
ciated with higher disease activity in rheumatic disease.
Increased fecal calprotectin at baseline was associated
with higher ASDASCRP, BASDAI, BASFI, CRP, and ESR at
5-year follow-up. Early prospective studies showed a link
between active gut inflammation and persistence of joint
and spine inflammation as well as more chronic radio-
graphic changes in the sacroiliac joint and spine [18, 27].
Researchers in two cross-sectional studies reported higher
fecal calprotectin in AS than in healthy control subjects
[28, 29]. One of the studies showed a positive correlation
between fecal calprotectin and BASDAI, BASFI, ESR, and
CRP [29]. In studies with the Belgian Inflammatory Arth-
ritis and spoNdylitis cohorT (GIANT) of early SpA, the
presence of histological gut inflammation was associated
with higher BASDAI and higher BASMI and was also
linked to a greater degree of bone marrow edema in the
sacroiliac joints visualized by magnetic resonance imaging
[13, 30]. The longitudinal results of our study support they
hypothesis that inflammation in the gut and the musculo-
skeletal system may be linked. If gut inflammation is the
cause or the consequence of locomotor disease is un-
known, however, and fecal calprotectin is only a surrogate
measure for gut inflammation.
In a recent report based on the GIANT cohort, fecal
calprotectin, serum calprotectin, and CRP were also
significantly higher in patients with microscopic gut
inflammation [31]. We found that serum calprotectin at
baseline was positively correlated with fecal calprotectin,
both at baseline and at 5-year follow-up, but serum
calprotectin was not a significant predictor for the devel-
opment of CD.
In the present study, the use of anti-TNF antibodies
was associated with lower fecal calprotectin, whereas use
of TNF receptor fusion proteins was associated with
higher levels of fecal calprotectin, at 5-year follow-up.
Infliximab and adalimumab, but not etanercept, are
efficacious in the treatment of CD and UC [32]. Simi-
larly, in earlier studies, more flares and onset of IBD
were observed in patients with AS treated with etaner-
cept than in patients treated with infliximab [33, 34].
Table 3 Development of gut inflammation in 204 patients with
ankylosing spondylitis between baseline and 5-year follow-up
Type of inflammation Baseline 5-Year
follow-up
Total
Diagnosis of Crohn’s disease 1 2 3
Diagnosis of ulcerative colitis 0 0 0
Diagnosis of lymphocytic colitis 1 0 1
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2 1
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The 5-year incidence of CD in the present study was
1.5%, which corresponds to an annual incidence of 294 new
cases per 100,000 person-years. This can be compared with
the highest reported annual incidence of CD in the general
population of 12.7 per 100,000 person years in Europe and
20.2 per 100,000 person-years in North America [35].
Mielants et al. reported an incidence of IBD of 5% in a co-
hort of 217 patients with SpA or AS during a median
follow-up of 5.5 years [19]. Similarly to our study, CD was
more common than UC in their study. In contrast to our
study, ileocolonoscopy was performed on all patients at
inclusion, and 49 patients underwent a second endoscopy.
Because patients with fecal calprotectin <200 mg/kg were
not examined with endoscopy in our study, cases with IBD
despite lower fecal calprotectin may have been missed.
Moreover, the earlier studies were performed in the “pre-
biologic era,” which may have affected the results. Fur-
thermore, a few patients with persistently elevated fecal
calprotectin declined ileocolonoscopy.
In our study, elevated fecal calprotectin and presence
of mucus in diarrhea at baseline were the only signifi-
cant predictors of the development of CD. The low
number of new cases of CD (n = 3) may have affected
the robustness of the results and the possibility of find-
ing other significant predictors.
The high use of NSAIDs among patients with AS is a
problem when studying gut inflammation. NSAID-
induced enteropathy is difficult to distinguish from AS-
associated gut inflammation and is associated with in-
creased fecal calprotectin [23]. In the present study,
NSAID use was stopped for 3 weeks before retesting
fecal calprotectin and before ileocolonoscopies, which
resulted in a drop of a median of 116 mg/kg in fecal cal-
protectin. We found that 3-week cessation of NSAID
use before testing fecal calprotectin was a reasonable
course of action and acceptable for most patients.
The strengths of the present study are its prospective
design with two measurement time points, the relatively
large and well-characterized cohort, and cessation of
NSAIDs before ileocolonoscopy at follow-up. The study’s
weaknesses are that ileocolonoscopy was not performed
in all patients, which may have resulted in a lower inci-
dence of IBD. The ileocolonoscopies were also per-
formed at different thresholds of fecal calprotectin at
baseline and 5-year follow-up (Fig. 1).
Conclusions
Fecal calprotectin was elevated in two-thirds of the patients
with AS and was positively associated with parameters
reflecting higher disease activity and poorer physical
function at both study visits. Use of NSAIDs and TNF
receptor fusions proteins was associated with higher levels
of fecal calprotectin, whereas use of anti-TNF antibodies
was associated with lower levels of fecal calprotectin.
Further studies are needed to prove whether anti-TNF
treatment has an effect on subclinical gut inflammation in
AS and whether it can prevent the development of IBD.
The 5-year incidence of CD was 1.5%, and elevated fecal
calprotectin at baseline was the strongest predictor of the
development of IBD. On the basis of these results, we
propose that fecal calprotectin may be a potential bio-
marker to identify patients with AS at risk of developing
IBD. Thus, fecal calprotectin quantification should be
considered, especially in patients with high disease activity
and gastrointestinal symptoms. If possible, NSAIDs should
be stopped temporarily before measuring fecal calprotectin
to reduce the confounding effect of NSAID enteropathy on
the measurement.
Abbreviations
AS: Ankylosing spondylitis; ASDAS: Ankylosing Spondylitis Disease Activity Score;
ASDASCRP: Ankylosing Spondylitis Disease Activity Score based on C-reactive
protein; BASDAI: Bath Ankylosing Spondylitis Disease Activity Index; BASFI: Bath
Ankylosing Spondylitis Functional Index; BAS-G: Bath Ankylosing Spondylitis
Patient Global Score; BASMI: Bath Ankylosing Spondylitis Metrology Index;
CD: Crohn’s disease; CRP: C-reactive protein; DMARD: Disease-modifying
antirheumatic drug; ELISA: Enzyme-linked immunosorbent assay;
ESR: Erythrocyte sedimentation rate; GIANT: Belgian Inflammatory Arthritis and
spoNdylitis cohorT; IBD: Inflammatory bowel disease; NSAID: Nonsteroidal
anti-inflammatory drug; ROC: Receiver operator characteristic;
SpA: Spondylarthritis; TNF: Tumor necrosis factor; UC: Ulcerative colitis
Acknowledgements
We thank all the patients who participated in the study.
Funding
This work was supported by grants from the Health and Medical Care
Executive Board of the Västra Götaland, Rune and Ulla Amlövs Foundation
for Rheumatology Research, Göteborg Association against Rheumatism, the
Swedish Association Against Rheumatism, the Medical Society of Göteborg,
and the Region Västra Götaland (agreement concerning research and
education of doctors), Controlling Chronic Inflammatory Diseases with
Combined Efforts (COMBINE), the Margareta Rheuma Research Foundation,
and the Swedish Society of Medicine.
Availability of data and materials
The datasets analyzed during the present study are available from the
corresponding author on reasonable request.
Authors’ contributions
EK participated in the design of the study, examined the patients, collected
data, performed statistical analyses, and drafted the manuscript. HS participated
in the design of the study, performed the ileocolonoscopies, and participated in
the collection and interpretation of data. AS was responsible for the fecal
analyses and interpretation of data. AD participated in the design of the study,
examined the patients, and collected data. HC participated in the design of the
study and the interpretation of data. LÖ participated in the design of the study
and the collection and interpretation of data. HFd’E supervised the study and
was responsible for study design and interpretation of data. All authors critically
reviewed the manuscript, approved the final version to be published, and
agreed to be accountable for all aspects of the work.
Competing interests




Klingberg et al. Arthritis Research & Therapy  (2017) 19:21 Page 8 of 9
Ethics approval and consent to participate
The study was approved by the regional ethics committee in Gothenburg
and was carried out in accordance with the Helsinki declaration.
All participants gave their written informed consent.
Author details
1Department of Rheumatology and Inflammation Research, Sahlgrenska
Academy at the University of Gothenburg, Guldhedsgatan 10A, S-413 46
Gothenburg, Sweden. 2Department of Internal Medicine, Södra Älvsborgs
Sjukhus, Borås, Sweden. 3Department of Internal Medicine and Clinical
Nutrition, Sahlgrenska Academy at the University of Gothenburg,
Gothenburg, Sweden. 4Department of Microbiology and Immunology,
Sahlgrenska Academy at the University of Gothenburg, Gothenburg, Sweden.
5Sweden School of Health and Education, University of Skövde, Skövde,
Sweden. 6Rheumatology Unit, Department of Public Health and Clinical
Medicine, Umeå University, Umeå, Sweden.
Received: 31 August 2016 Accepted: 6 January 2017
References
1. Reveille JD. Genetics of spondyloarthritis—beyond the MHC. Nat Rev
Rheumatol. 2012;8(5):296–304.
2. Jacques P, Van Praet L, Carron P, Van den Bosch F, Elewaut D.
Pathophysiology and role of the gastrointestinal system in
spondyloarthritides. Rheum Dis Clin North Am. 2012;38(3):569–82.
3. Thjodleifsson B, Geirsson AJ, Bjornsson S, Bjarnason I. A common genetic
background for inflammatory bowel disease and ankylosing spondylitis: a
genealogic study in Iceland. Arthritis Rheum. 2007;56(8):2633–9.
4. Bjarnason I, Helgason KO, Geirsson AJ, Sigthorsson G, Reynisdottir I,
Gudbjartsson D, et al. Subclinical intestinal inflammation and sacroiliac
changes in relatives of patients with ankylosing spondylitis.
Gastroenterology. 2003;125(6):1598–605.
5. Orchard TR, Wordsworth BP, Jewell DP. Peripheral arthropathies in
inflammatory bowel disease: their articular distribution and natural history.
Gut. 1998;42(3):387–91.
6. Orchard TR, Holt H, Bradbury L, Hammersma J, McNally E, Jewell DP, et al.
The prevalence, clinical features and association of HLA-B27 in sacroiliitis
associated with established Crohn’s disease. Aliment Pharmacol Ther.
2009;29(2):193–7.
7. de Vlam K, Mielants H, Cuvelier C, De Keyser F, Veys EM, De Vos M.
Spondyloarthropathy is underestimated in inflammatory bowel disease:
prevalence and HLA association. J Rheumatol. 2000;27(12):2860–5.
8. Baeten D, De Keyser F, Mielants H, Veys EM. Ankylosing spondylitis and
bowel disease. Best Pract Res. 2002;16(4):537–49.
9. Vavricka SR, Schoepfer A, Scharl M, Lakatos PL, Navarini A, Rogler G.
Extraintestinal manifestations of inflammatory bowel disease. Inflamm
Bowel Dis. 2015;21(8):1982–92.
10. Lee YH, Ji JD, Kim JS, Bak YT, Lee CH, Kim CH, et al. Ileocolonoscopic and
histologic studies of Korean patients with ankylosing spondylitis. Scand J
Rheumatol. 1997;26(6):473–6.
11. Mielants H, Veys EM, Cuvelier C, de Vos M. Ileocolonoscopic findings in
seronegative spondylarthropathies. Br J Rheumatol. 1988;27 Suppl 2:95–105.
12. Leirisalo-Repo M, Turunen U, Stenman S, Helenius P, Seppala K. High
frequency of silent inflammatory bowel disease in spondylarthropathy.
Arthritis Rheum. 1994;37(1):23–31.
13. Van Praet L, Van den Bosch FE, Jacques P, Carron P, Jans L, Colman R, et al.
Microscopic gut inflammation in axial spondyloarthritis: a multiparametric
predictive model. Ann Rheum Dis. 2013;72(3):414–7.
14. Cuvelier C, Barbatis C, Mielants H, De Vos M, Roels H, Veys E.
Histopathology of intestinal inflammation related to reactive arthritis.
Gut. 1987;28(4):394–401.
15. Mielants H, Veys EM, Cuvelier C, De Vos M, Goemaere S, De Clercq L, et al.
The evolution of spondyloarthropathies in relation to gut histology. II.
Histological aspects. J Rheumatol. 1995;22(12):2273–8.
16. Van Praet L, Jacques P, Van den Bosch F, Elewaut D. The transition of acute
to chronic bowel inflammation in spondyloarthritis. Nat Rev Rheumatol.
2012;8(5):288–95.
17. Stolwijk C, van Tubergen A, Castillo-Ortiz JD, Boonen A. Prevalence of
extra-articular manifestations in patients with ankylosing spondylitis: a
systematic review and meta-analysis. Ann Rheum Dis. 2015;74(1):65–73.
18. De Vos M, Mielants H, Cuvelier C, Elewaut A, Veys E. Long-term evolution of
gut inflammation in patients with spondyloarthropathy. Gastroenterology.
1996;110(6):1696–703.
19. Mielants H, Veys EM, De Vos M, Cuvelier C, Goemaere S, De Clercq L, et al.
The evolution of spondyloarthropathies in relation to gut histology. I.
Clinical aspects. J Rheumatol. 1995;22(12):2266–72.
20. Tibble J, Teahon K, Thjodleifsson B, Roseth A, Sigthorsson G, Bridger S, et al.
A simple method for assessing intestinal inflammation in Crohn’s disease.
Gut. 2000;47(4):506–13.
21. Foell D, Wittkowski H, Roth J. Monitoring disease activity by stool analyses:
from occult blood to molecular markers of intestinal inflammation and
damage. Gut. 2009;58(6):859–68.
22. Gisbert JP, McNicholl AG. Questions and answers on the role of faecal
calprotectin as a biological marker in inflammatory bowel disease. Dig Liver
Dis. 2009;41(1):56–66.
23. Higuchi K, Umegaki E, Watanabe T, Yoda Y, Morita E, Murano M, et al.
Present status and strategy of NSAIDs-induced small bowel injury. J
Gastroenterol. 2009;44(9):879–88.
24. Klingberg E, Carlsten H, Hilme E, Hedberg M, Forsblad-d’Elia H. Calprotectin
in ankylosing spondylitis – frequently elevated in feces, but normal in
serum. Scand J Gastroenterol. 2012;47(4):435–44.
25. van der Linden S, Valkenburg HA, Cats A. Evaluation of diagnostic criteria
for ankylosing spondylitis: a proposal for modification of the New York
criteria. Arthritis Rheum. 1984;27(4):361–8.
26. Sieper J, Rudwaleit M, Baraliakos X, Brandt J, Braun J, Burgos-Vargas R,
et al. The Assessment of SpondyloArthritis international Society (ASAS)
handbook: a guide to assess spondyloarthritis. Ann Rheum Dis. 2009;68
Suppl 2:ii1–44.
27. Mielants H, Veys EM, Cuvelier C, De Vos M, Goemaere S, De Clercq L,
et al. The evolution of spondyloarthropathies in relation to gut
histology. III. Relation between gut and joint. J Rheumatol.
1995;22(12):2279–84.
28. Matzkies FG, Targan SR, Berel D, Landers CJ, Reveille JD, McGovern DP, et al.
Markers of intestinal inflammation in patients with ankylosing spondylitis: a
pilot study. Arthritis Res Ther. 2012;14(6):R261.
29. Duran A, Kobak S, Sen N, Aktakka S, Atabay T, Orman M. Fecal calprotectin
is associated with disease activity in patients with ankylosing spondylitis.
Bosn J Basic Med Sci. 2016;16(1):71–4.
30. Van Praet L, Jans L, Carron P, Jacques P, Glorieus E, Colman R, et al. Degree
of bone marrow oedema in sacroiliac joints of patients with axial
spondyloarthritis is linked to gut inflammation and male sex: results from
the GIANT cohort. Ann Rheum Dis. 2014;73(6):1186–9.
31. Cypers H, Varkas G, Beeckman S, Debusschere K, Vogl T, Roth J, et al.
Elevated calprotectin levels reveal bowel inflammation in spondyloarthritis.
Ann Rheum Dis. 2016;75(7):1357–62.
32. Sandborn WJ, Hanauer SB, Katz S, Safdi M, Wolf DG, Baerg RD, et al.
Etanercept for active Crohn’s disease: a randomized, double-blind, placebo-
controlled trial. Gastroenterology. 2001;121(5):1088–94.
33. Braun J, Baraliakos X, Listing J, Davis J, van der Heijde D, Haibel H, et
al. Differences in the incidence of flares or new onset of inflammatory
bowel diseases in patients with ankylosing spondylitis exposed to
therapy with anti-tumor necrosis factor alpha agents. Arthritis Rheum.
2007;57(4):639–47.
34. Toussirot E, Houvenagel E, Goeb V, Fouache D, Martin A, Le Dantec P, et al.
Development of inflammatory bowel disease during anti-TNF-alpha therapy
for inflammatory rheumatic disease: a nationwide series. Joint Bone Spine.
2012;79(5):457–63.
35. Ye Y, Pang Z, Chen W, Ju S, Zhou C. The epidemiology and risk factors of
inflammatory bowel disease. Int J Clin Exp Med. 2015;8(12):22529–42.
Klingberg et al. Arthritis Research & Therapy  (2017) 19:21 Page 9 of 9
